Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Medicenna Therapeutics Corp

MDNA.TO ✓ COMPLIANTFree checks used up today ☆ Track — members

TSE · Healthcare · Biotechnology & Medical Research ·

Canada Micro Cap Analyst: BUY

Last Close

$0.30

▲ +2.44%

Market Cap $27.60M · Vol 7.58K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$27.60M

Micro Cap

Div Yield

N/A

EPS Growth

-63.81%

YoY

RSI (14)

57.89

Momentum

Beta

2.25

vs Market

52W High

$1.41

79.27% below

52W Low

$0.24

22.93% above

Volume

7.58K

Avg 43.54K

P/B

21.51

Price-to-book

ROE

-170.64%

Return on equity

Free Float

81.07%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Medicenna Therapeutics Corp (MDNA.TO) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does MDNA.TO pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-4.55%

+2.44%

+20.00%

-28.81%

YTD

-54.35%

-54.84%

+8.01%

-86.00%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-13,230,559.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-170.64%
ROA · ROIC	-99.95% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	21.51
P/FCF	N/A
EPS Growth	-63.81%
Outstanding Shares	92.30M

Technical Indicators

50-Day SMA	$0.31
200-Day SMA	$0.41
RSI (14)	57.89
Beta	2.25
52-Week High	$1.41
52-Week Low	$0.24

Volume Today	7.58K
Avg Daily Volume (30D)	43.54K
Relative Volume	0.17x
Volatility (10D)	61.34
Volatility (30D)	52.34
Free Float	81.07%

Analyst Consensus

BUY

Current Price $0.30

Mean Target $2.28

52W Low$0.24 52W High$1.41

Current

Target

$0.24 $1.41

Current Analyst target

+661.26% upside potential · 3 analysts

Identifiers

ExchangeTSE

FIGIBBG008MPLP12

ISINCA58490H1073

CountryCanada

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 10, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -6.02% ARGX.BR argenx SE -0.41% ARGX argenx SE -1.61% GMAB.CO Genmab A/S +1.30% GMAB Genmab A/S +1.09%

Company Profile

Medicenna Therapeutics Corp. is a clinical-stage immunotherapy company focused on developing highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Its long-acting IL-2 Superkine, MDNA11, is a IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Its IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials, including a Phase IIb trial for recurrent glioblastoma (GBM). Its early-stage high-affinity IL-2B biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Its early-stage BiSKITs (Bifunctional SuperKine ImmunoTherapies) and the T-MASK (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.